Clinical Trial: Kamlanoflast In Amyotrophic Lateral Sclerosis

U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07396818) titled 'Kamlanoflast In Amyotrophic Lateral Sclerosis' on Feb. 02.

Brief Summary: This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected.

Study Start Date: Feb., 2026

Study Type: INTERVENTIONAL

Condition: ALS (Amyotrophic Lateral Sclerosis) ALS Neuro-Degenerative Disease Neuro-Degenerative Diseases Motor Neuron Disease (MND)

Intervention: DRUG: Kamlanoflast

Low dose Kamlanoflast by oral administration

DRUG: Kamlanoflast

High dose Kamlanoflast by oral admini...